TY - JOUR
T1 - Randomized Pilot Trial on Optimal Treatment Strategy, Myocardial Changes, and Prognosis of Patients with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA)
AU - Serpytis, Rokas
AU - Majauskiene, Egle
AU - Navickas, Petras
AU - Lizaitis, Mindaugas
AU - Glaveckaite, Sigita
AU - Rucinskas, Kestutis
AU - Petrulioniene, Zaneta
AU - Valeviciene, Nomeda
AU - Samalavicius, Robertas Stasys
AU - Berukstis, Andrius
AU - Baranauskas, Arvydas
AU - Gargalskaite, Urte
AU - Laucevicius, Aleksandras
AU - Chen, Qin M.
AU - Alpert, Joseph S.
AU - Serpytis, Pranas
N1 - Funding Information: Funding: This study has received funding from the European Social Fund (project No 09.3.3-LMT-K-712-0148) under a grant agreement with Research Council of Lithuania (LMTLT). Publisher Copyright: © 2021
PY - 2022/1
Y1 - 2022/1
N2 - Background: Myocardial infarction with nonobstructive coronary arteries (MINOCA) remains an unresolved challenge. Many different diagnostic approaches are often required to diagnose, confirm, and evaluate MINOCA. The prevalence can be as high as 13% of all acute myocardial infarction patients, indicating that this condition is not rare. At this time, there have been no completed randomized clinical trials involving MINOCA patients, and a better understanding of the mechanisms and management of these patients is important. This exploratory analysis seeks to find possible etiologic factors, the value of novel biomarkers, and the effect of different treatment strategies in patients with MINOCA. Methods: This prospective randomized pilot trial will include 150 patients with MINOCA. A thorough clinical, laboratory, and imaging evaluation will be performed, including novel biomarkers and modern imaging techniques (heart magnetic resonance imaging and noninvasive testing). The duration of the enrollment is 18 months, and duration of the follow-up is 12 months from the enrollment of the first patient. Results: The trial is registered under www.clinicaltrials.gov: NCT04538924. The study is currently recruiting participants. Conclusions: Because MINOCA is not a benign disease, the results of the current investigation could inform future diagnostic and therapeutic strategies and enhance the understanding of MINOCA patients.
AB - Background: Myocardial infarction with nonobstructive coronary arteries (MINOCA) remains an unresolved challenge. Many different diagnostic approaches are often required to diagnose, confirm, and evaluate MINOCA. The prevalence can be as high as 13% of all acute myocardial infarction patients, indicating that this condition is not rare. At this time, there have been no completed randomized clinical trials involving MINOCA patients, and a better understanding of the mechanisms and management of these patients is important. This exploratory analysis seeks to find possible etiologic factors, the value of novel biomarkers, and the effect of different treatment strategies in patients with MINOCA. Methods: This prospective randomized pilot trial will include 150 patients with MINOCA. A thorough clinical, laboratory, and imaging evaluation will be performed, including novel biomarkers and modern imaging techniques (heart magnetic resonance imaging and noninvasive testing). The duration of the enrollment is 18 months, and duration of the follow-up is 12 months from the enrollment of the first patient. Results: The trial is registered under www.clinicaltrials.gov: NCT04538924. The study is currently recruiting participants. Conclusions: Because MINOCA is not a benign disease, the results of the current investigation could inform future diagnostic and therapeutic strategies and enhance the understanding of MINOCA patients.
KW - MINOCA
KW - Myocardial infarction
KW - Myocardial infarction with nonobstructive coronary arteries
UR - http://www.scopus.com/inward/record.url?scp=85117864818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117864818&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2021.08.023
DO - 10.1016/j.amjmed.2021.08.023
M3 - Article
C2 - 34562410
SN - 0002-9343
VL - 135
SP - 103
EP - 109
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 1
ER -